Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
1131 daily bars · split adjusted
Daily · Wilder smoothing
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 34.86 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 15.41 | Oscillator | Buy |
| Williams %R (14) | -85.71 | Oscillator | Buy |
| MACD (12, 26, 9) | -0.15 (Hist -0.02) | Oscillator | Strong Sell |
| Average Directional Index (14) | 24.48 (+DI 12.7 / -DI 25.7) | Trend | Sell |
Current price $1.93
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| May 29, 26 | Ascendiant Capital | maintain | Buy | Buy |
| Mar 25, 26 | Ascendiant Capital | maintain | Buy | Buy |
| Nov 20, 25 | Ascendiant Capital | maintain | Buy | Buy |
| Sep 19, 25 | Ascendiant Capital | maintain | Buy | Buy |
| Dec 13, 24 | Maxim Group | downgrade | Buy | Hold |
| Nov 27, 24 | Ascendiant Capital | maintain | Buy | Buy |
| Aug 26, 24 | Ascendiant Capital |
| EMA 20 | 2.14 | MA | Strong Sell |
| SMA 20 | 2.17 | MA | Strong Sell |
| EMA 50 | 2.33 | MA | Strong Sell |
| SMA 50 | 2.39 | MA | Strong Sell |
| SMA 200 | 2.93 | MA | Strong Sell |
| maintain |
| Buy |
| Buy |
| Jul 6, 22 | Maxim Group | maintain | Buy | Buy |
TTM vs. 5-year historical average (annual ratios)
| Metric | ACON | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | -0.3x | -0.9x · sector 20.7x | Discount |
| Forward P/E (FY26E) | -0.4x | EPS est. -4.74 | Elevated |
| Price / Book | 0.3x | -0.8x | Discount |
| Price / Sales | 66.4x | 88.7x | Discount |
| EV / EBITDA | 1.2x | -0.9x | Discount |
| Return on equity | -59.3% | — | Weak |
| Gross margin | -51.0% | -99.7% | Below hist. |
| Debt / Equity | 0.00 | -0.38 | Conservative |
| Piotroski / Altman Z | 2/9 | Z -2.38 | Distress |
Discounted cash flow model
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Aug 17, 26 | Williams Amanda M | director | P-Purchase | 5,857 @ $2.73 | $15.99K |
| Aug 14, 26 | Gould Gregory A | officer: CFO | P-Purchase | 10,000 @ $2.45 | $24.50K |
| Aug 13, 26 | Bond Ryan | director | P-Purchase | 21,122 @ $2.37 | $50.06K |
| Aug 13, 26 | Wesemann William | director | P-Purchase | 2,150 @ $2.34 | $5.03K |
| Aug 13, 26 | Neal David K | director | P-Purchase | 7,500 @ $2.40 | $18.00K |
| Aug 13, 26 | Ness Brent | director, officer: Chief Executive Officer | P-Purchase | 5,234 @ $2.31 | $12.09K |
| Jun 11, 26 | Bond Ryan | officer: Chief Strategy Officer | A-Award | 55,000 | — |
| Jun 11, 26 | Sequira Amanda Mae | director | A-Award | 20,000 | — |
Stock news · updated daily
BROOMFIELD, Colo., Oct. 22, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution) –Aclarion, Inc.
BROOMFIELD, Colo., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Aclarion (NASDAQ: ACON) announced today that it will participate in the 20th Annual LD Micro Main Event, taking place October 19-21, 2026 at the Luxe Sunset Boulevard Hotel in Los Angeles, California.
PR Audio: BROOMFIELD, Colo., October 8, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution) – Aclarion, Inc.
New criteria fully approved at nine of eleven active sites expected to significantly accelerate enrollment pace Initial readout timing to be updated by year-end based on demonstrated Q4 enrollment increases Overall trial duration remains on track BROOMFIELD, Colo., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced an update to the enrollment criteria and expected timing of the initial readout from its pivotal CLARITY clinical trial.
PR Audio: BROOMFIELD, Colo., September 29, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution) – Aclarion, Inc.
NYU Langone Health is a nationally recognized academic medical center with deep expertise in spine surgery, minimally invasive procedures, robotic spine surgery, and clinical research CLARITY is a prospective, randomized clinical trial designed to demonstrate Nociscan's ability to improve surgical outcomes for chronic low back pain Nociscan® aims to become the gold standard in identifying sources of low back pain through MR Spectroscopy (MRS) and Augmented Intelligence (AI) BROOMFIELD, Colo., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced NYU Langone Health as a new clinical site in its CLARITY (Chronic Low bAck pain Randomized Independent Trial studY) trial.
Aclarion, Inc. (NASDAQ: ACON - Get Free Report) was the target of a significant increase in short interest during the month of September. As of September 15th, there was short interest totaling 76,007 shares, an increase of 206.9% from the August 31st total of 24,767 shares. Based on an average daily volume of 39,191 shares, the
OptimizeRx (NASDAQ: OPRX - Get Free Report) and Aclarion (NASDAQ: ACON - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, valuation, analyst recommendations, risk, earnings, dividends and institutional ownership. Risk and Volatility OptimizeRx has a beta of 1.09,
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Aug 6, 2026 | -1.05 | -1.12 | Miss -6.7% | $25.21K |
| May 21, 2026 | -1.55 | -1.34 | Beat 13.5% | $20.00K |
| Feb 25, 2026 | -3.60 | -3.60 | Beat 0.0% | $20.00K |
| Nov 12, 2025 | -2.64 | -2.93 | Miss -11.0% | $18.94K |
| Aug 14, 2025 | -2.26 | -2.75 | Miss -21.7% | $19.32K |
| May 15, 2025 | -1,447.20 | -9.32 | Beat 99.4% | $18.99K |
SEC EDGAR filings · last 12 months
| Form | Filed | Accepted | Document |
|---|---|---|---|
| 4 | Aug 19, 2026 | 2026-08-19 08:30:04 | View |
| 4 | Aug 18, 2026 | 2026-08-18 08:30:03 | View |
| 4 | Aug 17, 2026 | 2026-08-17 08:30:09 | View |
| 4 | Aug 17, 2026 | 2026-08-17 08:30:06 | View |
| 4 | Aug 17, 2026 | 2026-08-17 08:30:05 | View |
| 4 | Aug 17, 2026 | 2026-08-17 08:30:03 | View |
| 10-Q | Aug 6, 2026 | 2026-08-06 09:00:40 | View |
| S-8 | Jul 9, 2026 | 2026-07-09 08:00:28 | View |
| 4 | Jun 12, 2026 | 2026-06-12 16:30:47 | View |
| 4 | Jun 12, 2026 | 2026-06-12 16:30:45 | View |
Proxy statement (DEF 14A) disclosures